VRCI Stock Overview
Verici Dx plc, an immuno-diagnostics development company, focuses on the kidney transplantation market.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Verici Dx plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.08 |
| 52 Week High | UK£0.19 |
| 52 Week Low | UK£0.055 |
| Beta | 1.48 |
| 1 Month Change | -17.95% |
| 3 Month Change | -11.11% |
| 1 Year Change | -52.94% |
| 3 Year Change | -88.41% |
| 5 Year Change | n/a |
| Change since IPO | -78.08% |
Recent News & Updates
Shareholder Returns
| VRCI | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 3.2% | -2.3% | -0.7% |
| 1Y | -52.9% | -29.4% | -1.8% |
Return vs Industry: VRCI underperformed the UK Biotechs industry which returned -29.6% over the past year.
Return vs Market: VRCI underperformed the UK Market which returned -2.4% over the past year.
Price Volatility
| VRCI volatility | |
|---|---|
| VRCI Average Weekly Movement | 7.5% |
| Biotechs Industry Average Movement | 7.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.5% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: VRCI's share price has been volatile over the past 3 months.
Volatility Over Time: VRCI's weekly volatility has decreased from 15% to 7% over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 14 | Sara Barrington | www.vericidx.com |
Verici Dx plc, an immuno-diagnostics development company, focuses on the kidney transplantation market. The company develops prognostic and diagnostic tests for kidney transplant patients. Its lead products comprise Tutivia, a post-transplant test focused on acute rejection, including sub-clinical rejection; and Clarava, a pre-transplant prognosis test for the risk of early acute rejection.
Verici Dx plc Fundamentals Summary
| VRCI fundamental statistics | |
|---|---|
| Market cap | UK£19.40m |
| Earnings (TTM) | -UK£9.02m |
| Revenue (TTM) | UK£15.28k |
1,270x
P/S Ratio-2.2x
P/E RatioIs VRCI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VRCI income statement (TTM) | |
|---|---|
| Revenue | US$19.00k |
| Cost of Revenue | US$3.00k |
| Gross Profit | US$16.00k |
| Other Expenses | US$11.23m |
| Earnings | -US$11.21m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.046 |
| Gross Margin | 84.21% |
| Net Profit Margin | -59,015.79% |
| Debt/Equity Ratio | 0% |
How did VRCI perform over the long term?
See historical performance and comparison